Search Results
Your search for ,wAS matches 27425 pages
Showing 6901 - 6950Margaret von Mehren, MD, Appointed New Vice Chair of Department of Hematology/Oncology at Fox Chase
Margaret von Mehren, MD, Chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new Vice Chair of the Department of Hematology/Oncology. “It is an honor to serve the Department of Hematology and Oncology, which I have been a member of since 1993,...
Iberia Romina Sosa, MD, PhD, Appointed New Chief of Division of Hematology at Fox Chase
Iberia Romina Sosa, MD, PhD, Associate Professor at Fox Chase Cancer Center, was recently appointed as the new Chief of the Division of Hematology in the Department of Hematology/Oncology. “I feel truly privileged to have been offered this role and to have the opportunity to work with such a...
CHIP Mutations ‘Surprisingly’ Associated With Lower Risk of Alzheimer’s Disease
The presence of clonal hematopoiesis of indeterminate potential, or CHIP, increases the risk of developing a myeloid malignancy and also cardiovascular disease—which are well-established findings—but it may also protect against developing Alzheimer’s disease, according to findings reported at the...
Expert Point of View: Matthew Genyeh Mei, MD
American Society of Hematology (ASH) session co-moderator Matthew Genyeh Mei, MD, Associate Professor, Hematologic Malignancies and Stem Cell Transplantation Institute of City of Hope in Southern California, said the studies of checkpoint inhibitors in newly diagnosed and previously treated Hodgkin ...
Combinations Advance the Power of Pembrolizumab in Hodgkin Lymphoma
Pembrolizumab monotherapy is an established treatment strategy for relapsed or refractory classical Hodgkin lymphoma. In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to...
Laura Bukavina, MD, MPH, Wins ASCO Genitourinary Conquer Cancer Merit Award for Microbiome Research in Bladder Cancer
Laura Bukavina, MD, MPH, a Urologic oncology fellow at Fox Chase Cancer Center, has been awarded the ASCO Genitourinary Conquer Cancer Merit Award. She presented the winning abstract, which characterizes the gut microbiome of patients with bladder cancer, at the 2022 ASCO Genitourinary (GU) Cancers ...
American Cancer Society Reports Breast Cancer Is Now the Leading Cause of Cancer Mortality in Black Women
Breast cancer has surpassed lung cancer as the leading cause of cancer mortality among Black women as of 2019. This news is one of the key findings in Cancer Statistics for African American/Black People 2022, published recently in CA: A Cancer Journal for Clinicians and its consumer-friendly...
Grieving the Loss of Sexual Intimacy as a Result of Cancer and Its Treatment
About 5 years ago, I began experiencing some digestive issues that I initially blamed on the stress from coping with my mother’s diagnosis of Alzheimer’s disease. But after 2 weeks of unrelenting symptoms, including abdominal pain, a change in my bowel habits, and rectal bleeding, I saw my primary...
Expert Point of View: Stefano Cascinu, MD
Stefano Cascinu, MD, of the Comprehensive Cancer Center, Università Vita-Salute, IRCCS-Ospedale San Raffaele, Milan, Italy, was the invited discussant of KEYNOTE-5901 and CheckMate 649.2 “These landmark studies could change the treatment paradigm of advanced esophageal and gastric cancers. They...
Cancer in the Arab World: Addressing Challenges to Improve Outcomes
I returned home to the United Arab Emirates in 2017, following my oncology fellowship training and work experience in the United States. I immediately realized that I am now dealing with a considerably different cancer patient population in terms of age of onset, stage at presentation, awareness...
Checkpoint Inhibitors in Esophagogastric Cancer: Updates of Landmark Trials
Updates of landmark trials of immune checkpoint inhibitors as first-line therapy for advanced HER2-negative esophagogastric cancers were presented at the 2022 ASCO Gastrointestinal Cancers Symposium. The studies upheld previous findings of an overall survival benefit when these agents are paired...
From a Low-Income Family in Puerto Rico, to a Leadership Role in Oncology for Gerardo Colón-Otero, MD
In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Gerardo Colón-Otero, MD, Professor of Medicine at Mayo Clinic College of Medicine, Past Chair of the Division of Hematology/Oncology at the Mayo Clinic in Florida, and Vice Dean at Mayo Clinic Alix School of...
Report on COVID-19 Outlines the Pandemic’s Negative Impact on Patient Care and Clinical Research—and the Lessons Learned
Patients with cancer are not only at an increased risk for developing severe COVID-19, but also face cancer treatment delays and interruptions due to the pandemic, potentially worsening cancer outcomes, according to the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. In...
Expert Point of View: Christopher Willett, MD
Christopher Willett, MD, Professor and Chair of the Department of Radiation Oncology at Duke University in Durham, North Carolina, shared his thoughts on the findings of the study by Lumish et al1 with The ASCO Post. He first noted the shift in recent years toward total neoadjuvant therapy in the...
Massage for Pain Management in the Cancer Population
Guest Editor’s Note: Pain is a debilitating symptom experienced by many patients with cancer that negatively impacts their quality of life. Massage therapy, historically used for relaxation and pain relief, plays an important supportive role in oncology settings. In this installment of The ASCO...
Expert Point of View: Samuel J. Klempner, MD
Samuel J. Klempner, MD, Associate Professor at Massachusetts General Hospital and Harvard Medical School, commented on the NEONIPIGA study for The ASCO Post. “This study was the first prospective data set to show what many have suspected—that neoadjuvant immune checkpoint blockade would lead to a...
Neoadjuvant Checkpoint Inhibitor Doublet Yields Complete Responses in Gastroesophageal Cancers
In patients with resectable microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) gastric and gastroesophageal junction adenocarcinoma, dual checkpoint inhibition with ipilimumab and nivolumab given as neoadjuvant therapy led to a pathologic complete response rate of 58.6%,...
Expert Point of View: Celestia S. Higano, MD
MAGNITUDE is challenging from a statistical point of view,” said formal discussant Celestia S. Higano, MD, currently Adjunct Professor, Department of Urologic Sciences at the University of British Columbia, Vancouver, Canada, and formerly of Fred Hutchinson Cancer Research Center in Seattle....
‘Potential for Curative Intent’
Findings from the international phase II KEYNOTE-158 trial of pembrolizumab among women with previously treated microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) endometrial tumors “suggest a long-term benefit to patients,” stated the trial’s lead author David M. O’Malley, ...
Expert Point of View: Benoit Rousseau, MD, PhD
Benoit Rousseau, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, called the findings of the phase II GERCOR NIPICOL trial “interesting and convincing.” Long-term follow-up showed the 3-year progression-free survival rate to be 70% after just 1 total year of treatment with nivolumab...
NIPICOL Trial: Promising Outcomes With Shorter Duration of Checkpoint Inhibition in Metastatic Colorectal Cancer
The phase II GERCOR NIPICOL study evaluated 1 year of treatment with nivolumab plus ipilimumab in patients with chemotherapy-resistant metastatic colorectal cancer whose tumors were microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). With this shortened treatment duration,...
Robust and Durable Responses to Pembrolizumab in Patients With Previously Treated MSI-H/dMMR Endometrial Cancer
“Robust and clinically meaningfulantitumor activity,” with durable responses and “encouraging survival outcomes,” were reported among patients with previously treated microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) endometrial tumors who received pembrolizumab in the...
Noninvasive Diagnosis of CNS Lymphoma Possible Through ctDNA
Circulating tumor DNA (ctDNA) is readily detectable in the plasma and cerebrospinal fluid of patients with central nervous system (CNS) lymphoma and is a strong prognostic biomarker for outcomes, a team of researchers from Germany and Stanford University reported at the 2021 American Society of...
Research Outlines Obstetric and Perinatal Outcomes for Female Survivors of Childhood Cancer
Survivors of childhood cancer who become pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study published by Zgardau et al in the Journal of the National Cancer Institute. Their children also don’t have higher risks of birth defects ...
Study Finds World Trade Center First Responders Have High Burden of Clonal Hematopoiesis
Scientists have determined that first responders to the World Trade Center during the September 11, 2001, terrorist attacks have increased levels of mutations that may escalate their risk for blood cancers or cardiovascular disease, according to a study published by Jasra et al in Nature Medicine....
SBRT in Combination With Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Pancreatic Cancer
In a Chinese single-institution phase II trial reported in The Lancet Oncology, Zhu et al found that stereotactic body radiotherapy (SBRT) followed by pembrolizumab plus trametinib improved overall survival vs SBRT followed by gemcitabine in patients with postresection, KRAS-mutant, PD-L1–positive...
CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas
“The mind is not a vessel to be filled but a fire to be kindled.” —Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the...
Linda Fleisher, PhD, MPH, Appointed Co-Chair of American Cancer Society’s National Navigation Roundtable
Linda Fleisher, PhD, MPH, Associate Research Professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, was recently appointed Co-Chair of the American Cancer Society’s National Navigation Roundtable. Patient navigators act as intermediaries between patients and...
Monica Bertagnolli, MD, FACS, FASCO, Joins Prevent Cancer Foundation Board of Directors
Monica Bertagnolli, MD, FACS, FASCO, was recently elected to the Prevent Cancer Foundation’s Board of Directors.Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School and a member of the Gastrointestinal Cancer and Sarcoma Disease...
Atul Gawande, MD, MPH, Appointed to Senior Post at U.S. Agency for International Development
On December 17, 2021, the U.S. Senate confirmed President Joe Biden’s nomination of Atul Gawande, MD, MPH, as Assistant Administrator of Global Health Development at the U.S. Agency for International Development (USAID). Dr. Gawande assumed the new role in January 2022. Dr. Gawande’s role at USAID ...
Humanitarian Paul Farmer, MD, PhD, Dies at 62
"One of the great advocates for the poorest and sickest of our planet.” —Nobel Peace Prize laureate Archbishop Desmond Tutu “Our mission is to provide a preferential option for the poor in health care. By establishing long-term relationships with sister organizations ...
Risk of COVID-19 Infection and Complications Among Survivors of Childhood, Adolescent, and Young Adult Cancers
In a Canadian population-based study reported in the Journal of Clinical Oncology, Gupta et al found that survivors of childhood, adolescent, and young adult cancers were not at a greater risk of COVID-19 infection or severe complications of infection compared with matched controls without cancer....
Comparison of Multiparametric Ultrasound and Multiparametric MRI for the Diagnosis of Prostate Cancer
In the prospective paired-cohort CADMUS study reported in The Lancet Oncology, Grey et al found that patients at risk of prostate cancer had a similar likelihood of being diagnosed with clinically significant cancer with the use of multiparametric ultrasound vs multiparametric magnetic resonance...
Updated Findings on T-DXd in Gastrointestinal Malignancies
Updates of phase II studies evaluating fam-trastuzumab deruxtecan-nxki (T-DXd) in gastrointestinal cancers were presented at the 2022 ASCO Gastrointestinal Cancers Symposium, continuing to offer support for the antibody-drug conjugate in these malignancies. In HER2-expressing gastric cancer, T-DXd...
Symptom Monitoring Intervention for Hospitalized Patients With Advanced Cancer
In a single-institution study reported in JAMA Oncology, Nipp et al found that a symptom monitoring intervention for patients hospitalized with advanced cancer did not increase proportions of days with improved symptoms, nor reduce length of hospital stay or unplanned readmission rates. Study...
Study Evaluates Whether ctDNA Has Demonstrable Advantage Over Standard Surveillance Methods for Colorectal Cancer
Researchers at City of Hope published data pointing to the limitations of a popular liquid biopsy that is used to detect the recurrence of colorectal cancer in patients who who have undergone surgical resection. The findings were published in JAMA Network Open by Marwan Fakih, MD, and colleagues....
Risk of Major Adverse Cardiovascular Events With Combined Immune Checkpoint Inhibition and VEGFR Inhibition in Patients With Advanced RCC
As reported in the Journal of Clinical Oncology by Brian I. Rini, MD, and colleagues, prospective cardiovascular monitoring in the phase III JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC) showed that patients with higher baseline troponin T levels receiving the combination of the...
Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Tang et al found that elective upper-neck irradiation sparing the uninvolved neck was noninferior in regional relapse–free survival vs standard whole-neck irradiation in previously untreated patients with nasopharyngeal carcinoma. Study...
(Epi)genetic Predisposing Factors in Wilms Tumor
In a Dutch study reported in the Journal of Clinical Oncology, Janna A. Hol, MD, and colleagues found that (epi)genetic predisposing factors could be identified in one-third of children diagnosed with Wilms tumor. As stated by the investigators, “Wilms tumor is associated with (epi)genetic...
Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer
Advanced radiotherapy techniques can reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented by Neal S. McCall, MD, at the 2022 Multidisciplinary Head and Neck Cancers Symposium (Abstract...
Study Defines Stem Cell Groups That May Drive Development of Myelodysplastic Syndromes
Researchers have discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) may be caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with...
Pathologic Response of Index Lymph Node and Concordance With Total Nodal Basin Pathologic Response in Stage III Melanoma
In a retrospective analysis reported in JAMA Surgery, Reijers et al found that pathologic response in largest lymph node metastasis (index lymph node [ILN]) was highly concordant with response in the total lymph node bed in patients with stage III melanoma receiving neoadjuvant...
How Does Intake of Unprocessed Red Meat and Processed Meat Impact Risk of Disease Recurrence and Mortality in Patients With Colon Cancer?
In a prospective cohort study reported in JAMA Network Open, Erin L. Van Blarigan, ScD, and colleagues found that higher intake of unprocessed red meat or processed meat was not associated with poorer recurrence-free or overall survival in patients with stage III colon cancer. As stated by the...
Mutations Associated With Resistance to Noncovalent BTK Inhibitors in Patients With CLL
In a study reported in The New England Journal of Medicine, Wang et al identified mutations that conferred resistance to noncovalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL) and found that some also conferred resistance to covalent BTK...
FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC
On March 4, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with platinum-doublet chemotherapy for adult patients with resectable non–small cell lung cancer (NSCLC) in the neoadjuvant setting. This represents the first FDA approval for neoadjuvant therapy for...
Karim Fizazi, MD, PhD, on Prostate Cancer: Early Results From the CYPIDES Trial of ODM-208
Karim Fizazi, PhD, MD, of Gustave Roussy and University of Paris-Saclay, discusses results from a first-in-human phase I/II trial, which showed that administering ODM-208—an oral, nonsteroidal inhibitor of the enzyme CYP11A1—to men with metastatic castration-resistant prostate cancer who were...
Study Finds Taller Adults May Be at Increased Risk for Colorectal Cancer
A new meta-analysis adds to evidence that taller adults may be more likely than shorter ones to develop colorectal cancer or colon polyps that can later become malignant. While the association between taller height and colorectal cancer has been previously investigated, researchers from Johns...
Patients With Merkel Cell Carcinoma Face 40% 5-Year Recurrence Rate, According to Recent Study
Patients treated for Merkel cell carcinoma face a 5-year recurrence rate of 40%—markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published by McEvoy et al in JAMA Dermatology. Additionally, in the study cohort of more than 600 patients, 95% of...
Addition of Selumetinib to Adjuvant Radioactive Iodine in High-Risk Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Ho et al, the phase III ASTRA trial showed no improvement in complete remission rate with the addition of selumetinib to adjuvant radioactive iodine (RAI) in patients with high-risk differentiated thyroid cancer. As stated by the investigators,...
Addition of BCL-XL/BCL-2 Inhibitor Navitoclax to Ongoing Ruxolitinib in Patients With Myelofibrosis With Disease Progression or Suboptimal Response
In a phase II trial reported in the Journal of Clinical Oncology, Harrison et al found that the BCL-XL/BCL-2 inhibitor navitoclax showed activity in patients with myelofibrosis with disease progression or suboptimal response during ongoing ruxolitinib treatment. As stated by the investigators,...
